A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is: Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer? Participants will be randomised to receive either trilaciclib or placebo.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Confirmed diagnosis of Limited-Stage Small Cell Lung Cancer
• Complete recovery from prior anti-tumor surgical procedures
• Measurable and evaluable disease through tumor assessment
• Willingness to participate and sign informed consent form
Locations
United States
California
Pharmacosmos Investigational Site
RECRUITING
Oakland
Contact Information
Primary
Pharmacosmos A/S Clinical and non-clinical research
info@pharmacosmos.com
+4559485959
Time Frame
Start Date: 2026-06-30
Estimated Completion Date: 2027-06
Participants
Target number of participants: 120
Treatments
Experimental: Trilaciclib
Receives trilaciclib
Placebo_comparator: Placebo
Receives placebo
Related Therapeutic Areas
Sponsors
Leads: Pharmacosmos A/S